article thumbnail

Nestlé divests peanut allergy treatment Palforzia to Stallergenes Greer

Pharmaceutical Technology

Nestlé has sold its peanut allergy drug Palforzia to Swiss biopharma Stallergenes Greer harma, concluding a year-long strategic review.

Allergies 299
article thumbnail

Xolair amplifies reach after FDA approval for treating food allergies 

Pharmaceutical Technology

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Allergies 236
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Groundbreaking mRNA Therapy Appears To Prevent and Treat Peanut Allergies in Mice

AuroBlog - Aurous Healthcare Clinical Trials blog

More treatments – and faster-acting treatments – for peanut allergies are urgently needed, and a new study outlines a promising drug technology based around a tiny nanoparticle just a few billionths of a meter in size. In tests on mice, the nanoparticle reversed peanut allergies and prevented them from developing in the first place.

Allergies 235
article thumbnail

Ligelizumab by Novartis for Food Allergy: Likelihood of Approval

Pharmaceutical Technology

Ligelizumab is under clinical development by Novartis and currently in Phase III for Food Allergy.

Allergies 187
article thumbnail

Nestle gives up on peanut allergy treatment after sluggish sales

Bio Pharma Dive

The FDA-approved therapy, called Palforzia, was little used, leading Nestle to abandon a business it had secured in a $2.6 billion deal three years ago.

Allergies 328
article thumbnail

CBC acquires UCB’s neurology and allergy business in China

Pharmaceutical Technology

CBC Group has completed the strategic acquisition of UCB's mature neurology and allergy business in China for $680m.

Allergies 130
article thumbnail

CHMP recommends oral peanut allergy immunotherapy treatment for toddlers  

Pharmaceutical Technology

The EMA’s CHMP has endorsed expanding the use of Palforzia to toddlers aged one to three years with peanut allergies.

Allergies 130